Anzeige
Mehr »
Mittwoch, 05.08.2026 - Börsentäglich über 12.000 News
China verschärft den Druck - Heavy Rare Earths werden zum geopolitischen Machtinstrument
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVR6 | ISIN: FR00140048X2 | Ticker-Symbol: 9W8
Lang & Schwarz
05.08.26 | 11:00
1,470 Euro
-0,34 % -0,005
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IKONISYS SA Chart 1 Jahr
5-Tage-Chart
IKONISYS SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,4601,48011:00

Aktuelle News zur IKONISYS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:26XFRA 9W8: WIEDERAUFNAHME/RESUMPTION52FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
DoIkonisys SA Reports its Full-Year Financial Results for 2025 and Provides an Update on Its Latest Developments451Total revenue up 52.6% to €1.64 million (vs. €1.08 million in 2024), driven by Hospitex' full-year contribution and the progressive rollout of Aliko Scientific's offering EBITDA improved...
► Artikel lesen
IKONISYS Aktie jetzt für 0€ handeln
23.07.Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project-
23.07.Aliko Scientific Tochter unterzeichnet Vereinbarung für Krebs-Screening in Usbekistan-
23.07.Aliko Scientific unit signs Uzbekistan cancer screening deal2
23.07.Aliko Scientific: Hospitex International Signs First Agreement With the Uzbek Oncology Institute for the Feasibility Study of a National Urine24 Screening Project258Confirmation of the growing international interest in Urine24 and significant recognition of Aliko Scientific's expertise in large-scale oncological diagnostic solutions Immediate launch...
► Artikel lesen
19.06.Aliko Scientific: Update on the suspension of trading of ALIKO shares on Euronext Growth Paris and postponement of the publication of the 2025 annual financial report1
15.06.XFRA 9W8: AUSSETZUNG/SUSPENSION131DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILIKONISYS EO 0,5...
► Artikel lesen
25.05.Aliko Scientific gründet Joint Venture in Brasilien zur Herstellung von FISH-Sonden1
25.05.Aliko Scientific signs Brazil JV to manufacture FISH probes1
25.05.Aliko Scientific SA: Aliko Scientific Signs Memorandum of Understanding with BioBrasil for Brazilian FISH Probe Manufacturing Joint Venture499Aliko Scientific signs Brazilian JV with BioBrasil to manufacture proprietary FISH probes for global diagnostic markets New "instrument probes" model aims to create recurring revenues and...
► Artikel lesen
19.05.Aliko Scientific SA: Aliko Scientific Announces Award of Major Five-Year Public Tender at Federico II University Hospital360Execution of the long-term strategy focused on recurring revenue and developing opportunities for sustainable growth Contract with a potential total value of approximately €620,000, over...
► Artikel lesen
11.05.Aliko Scientific SA: Aliko Scientific Signs Strategic Memorandum of Understanding with Cellay Inc. and Secures First Commercial Customer in Arizona451Regulatory News: Aliko Scientific SA ("Aliko Scientific" or the "Company") (Euronext Growth Paris: ALIKO), an industrial and financial holding company focused on advanced oncology diagnostics...
► Artikel lesen
10.03.Aliko Scientific signs Italy distribution deal for bladder test1
10.03.Aliko Scientific: Hospitex International Signs Strategic Distribution Agreement With Naturneed for Urine24, Strengthening Its Commercial Footprint in the Italian Urology Diagnostics Market424Regulatory News: Hospitex International, part of Aliko Scientific Group (Ticker: ALIKO), announces the signing of a strategic distribution agreement with Naturneed for the commercialization...
► Artikel lesen
24.02.Aliko Scientific: Outstanding Success at WHX Labs Dubai With 172 Commercial Leads and Strong Global Interest in the New Integrated Oncology Diagnostics Platform442Regulatory News: Aliko Scientific SA (Ticker: ALIKO) previously Ikonisys SA, announces a highly successful first market appearance at WHX Labs Dubai, the world's largest medical trade exhibition...
► Artikel lesen
18.02.Aliko Scientific: Francesco Trisolini Appointed as New Group CEO to Pursue the Implementation of the Approved Industrial Plan476Regulatory News: Aliko Scientific SA (Ikonisys SA Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution...
► Artikel lesen
19.12.25Ikonisys SA: Ikonisys finalized a Capital Increase and Debt Conversion of EUR 2.72 million with strategic investment from Avantgarde Srl and Alberto Previtali514Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis...
► Artikel lesen
04.12.25Ikonisys SA: Ikonisys: Cytofast Auto: The First Fully Automatic Universal Monolayer Cytology Processor Is Born403Regulatory News: Hospitex international, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices...
► Artikel lesen
24.11.25Ikonisys SA: Ikonisys: Hospitex Initiates International Dialogues for Pilot Projects in Oncology Diagnostics Following ADB Delegation Visit522Regulatory News: Hospitex, the fully owned Italian subsidiary of Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology medical devices, announces...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1